XML 21 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Jan. 01, 2021
Current assets:    
Cash and cash equivalents $ 647,169 $ 319,217
Short-term investments 819,905 887,319
Trade receivables, net 282,650 160,875
Inventory 27,493 20,973
Prepaid expenses and other current assets 57,530 57,011
Total current assets 1,834,747 1,445,395
Long-term investments 371,112 330,751
Property and equipment, net 104,031 67,384
Deferred tax assets, net 111,663 156,711
Goodwill 63,684 63,684
Other long-term assets 131,002 73,408
Total assets 2,616,239 2,137,333
Current liabilities:    
Accounts payable 24,258 23,632
Accrued compensation and benefits 61,969 51,189
Accrued clinical trial liabilities 77,544 52,251
Rebates and fees due to customers 33,700 20,683
Accrued collaboration liabilities 86,753 12,456
Other current liabilities 53,366 44,447
Total current liabilities 337,590 204,658
Long-term portion of deferred revenue 8,739 3,755
Long-term portion of operating lease liabilities 51,272 49,086
Other long-term liabilities 8,023 721
Total liabilities 405,624 258,220
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 318,842 and 311,627 at December 31, 2021 and 2020, respectively 319 312
Additional paid-in capital 2,427,561 2,321,895
Accumulated other comprehensive income (758) 4,476
Accumulated deficit (216,507) (447,570)
Total stockholders’ equity 2,210,615 1,879,113
Total liabilities and stockholders’ equity $ 2,616,239 $ 2,137,333